Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis

Molecular Therapy

Volumn 6, Issue 5, 2002, Pages 591-600

  Kim, Seon Hee ^a   Lechman, Eric R ^a   Kim, Sunyoung ^b   Nash, Joan ^a   Oligino, Thomas J ^a   Robbins, Paul D ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Seoul National University   (South Korea)

Author keywords

Arthritis; Gene therapy; IL 1Ra; Inflammation; Retroviral vectors; sTNFR

Indexed keywords

ANTIGEN; DNA; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RETROVIRUS VECTOR; TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 1 RECEPTOR; PROTEOGLYCAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHONDROPROTECTION; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FIBROBLAST; GENE DELIVERY SYSTEM; GENE THERAPY; INFLAMMATORY CELL; NONHUMAN; PROTEIN EXPRESSION; RABBIT; RHEUMATOID ARTHRITIS; ANIMAL; ARTHRITIS; BIOLOGICAL MODEL; CARTILAGE; DISEASE MODEL; GENE TRANSFER; GENE VECTOR; GENETICS; INFLAMMATION; METABOLISM; METHODOLOGY; MOUSE; PLASMID; RETROVIRUS; TRANSGENE;

ANIMALIA; ORYCTOLAGUS CUNICULUS; UNIDENTIFIED RETROVIRUS;

ANIMALS; ARTHRITIS; CARTILAGE; DISEASE MODELS, ANIMAL; FIBROBLASTS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INFLAMMATION; MICE; MODELS, BIOLOGICAL; PLASMIDS; PROTEOGLYCANS; RABBITS; RECEPTORS, INTERLEUKIN-1; RECEPTORS, TUMOR NECROSIS FACTOR; RETROVIRIDAE; TRANSGENES;

EID: 0036853027     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(02)90711-2     Document Type: Article

References (41)

1. Arend, W. P., and Dayer, J. M. (1995). Inhibition of the production and effects of interleukin-1 and tumor necrosis factor-α in rheumatoid arthritis. Arthritis Rheum. 38: 150-160.
2. Evans, C., and Robbins, P. D. (1994). Prospects for treating arthritis by gene therapy. J. Rheumatol. 21: 779-782.
3. Robbins, P. D., and Evans, C. H. (1996). Prospects for treating autoimmune and inflammatory diseases by gene therapy. Gene Ther. 3: 187-189.
4. Zoja, C., et al. (1991). Interleukin-1β and tumor necrosis factor-α induce gene expression and production of leukocyte chomotactic factor, colony-stimulating factors, and interleukin-6 in human mesangial cells. Am. J. Pathol. 138: 991-1003.
5. Aloisi, F., et al. (1991). Production of hemolymphopoietic cytokines (IL-6, Il-8, colony-stimulating factors) by normal human astrocytes in response to IL-1β and tumor necrosis factor-α. J. Immunol. 149: 2358-2366.
6. Pang, G., Couch, L., Batey, R., Clancy, R., and Cripps, A. (1994). GM-CSF, IL-1α, IL-1β, IL-6, IL-8, IL-10, ICAM-1 and VCAM-1 gene expression and cytokine production in human duodenal fibroblasts stimulated with lipopolysaccharide, IL-1α and TNF-α. Clin. Exp. Immunol. 96: 437-443.
7. al-Janadi, M., al-Balla, S., al-Dalaan, A., and Raziuddin, S. (1993). Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J. Clin. Immunol. 13: 58-67.
8. Toussirot, E., et al (1994). Serum levels of interleukin 1-β, tumor necrosis factor-α, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol. Int. 13: 175-180.
9. Hidaka, T., et al (2001). Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. J. Clin Apheresis 16: 74-81.
10. Klimiuk, P. A. et al. (2001). Serum cytokines in different histological variants of rheumatoid arthritis. J. Rheumatol 28: 1211-1217.
11. Loetscher, H., Steinmetz, M., and Lesslauer, W. (1991). Tumor necrosis factor: receptors and inhibitors. Cancer Cells 3: 221-226.
12. Abe, Y., et al. (1993). Role of 55-and 75-kDa tumor necrosis factor membrane receptors in the regulation of intercellular adhesion molecules-1 expression by HL-60 human promyelocytic leukemia cells in vitro. J. Immunol. 150: 5070-5079.
13. McIntyre, K. W., et al. (1991). Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J. Exp. Med. 173: 931-939.
14. Svenson, M., Hansen, M. B., Heegaard, P., Abell, K., and Bendtzen, K. (1993). Specific binding of interleukin 1 (IL-1) β and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble Il-1 receptor type I. Cytokine 5: 427-435.
15. Arend, W. P. (1993). IL-1 antagonism in inflammatory arthritis. Lancet 341: 155-156.
16. Bandara, G., et al. (1993). Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc. Natl. Acad. Sci. USA 90: 10764-10768.
17. Ghivizzani, S. C., et al (1998). Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor α soluble receptor to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc. Natl. Acad. Sci. USA 95: 4613-4618.
18. Mori, L., Iselin, S., De Libero, G., and Lesslauer, W. (1996). Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-lgG1-treated and TNFR1-deficient mice. J. Immunol. 157: 3178-3182.
19. Joosten, L. A., Helsen, M. M., van de Loo, F. A., and van den Berg, W. B. (1996). Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF-α, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum. 39: 797-809.
20. Elliott, M. J., et al. (1994). Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 344: 1125-1127.
21. Elliott, M. J., et al. (1994). Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110.
22. Evans, C. H., et al. (1996). Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum. Gene Ther. 7: 261-1280.
23. Moreland, L. W., et al. (1997). Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337: 141-147.
24. Bresnihan, B., et al. (1998). Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41: 2196-2204.
25. weinblatt, M. E., et al. (1999). A Trial of etanercept, a recombinant tumor necrosis factor receptor-Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340: 253-259.
26. Jiang, Y., et al (2000). A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43: 1001-1009.
27. Lechman, E. R., et al. (1999). Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. J. Immunol. 163: 2202-2208.
28. Whalen, J. D., et al. (1999). Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J. Immunol. 162: 3625-3632.
29. Miagkov, A. V., et al. (1998). NF-(B activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc. Natl. Acad. Sci. USA 95: 13859-13864.
30. Boyle, D. L., et al (1999). Intra-articular IL-4 gene therapy in arthritis: anti-inflammatory effect and enhanced th2 activity. Gene Ther. 6: 1911-1918.
31. Kim, S.-H. et al. (2000). Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4. Arthritis Res. 2: 293-302.
32. Whalen, J. D., Thomson, A. W., Lu, L., Robbins, P. D., and Evans, C. H. (2001). Viral IL-10 gene transfer inhibits DTH responses to soluble antigens: evidence for involvement of genetically modified dendritic cells and macrophages. Mol. Ther. 4: 543-550.
33. Kim, S.-H., et al. (2001). Effective treatment of established murine collagen-induced anthritis by systemic administration of dendritic cells genetically modified to express IL-4. J. Immunol. 166: 3499-3505.
34. Kim, S.-H., Kim, S., Oligino, T. J., and Robbins, P. D. (2000). Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol. Ther. (in press).
35. Kim, S.-H., et al. (1998). Construction of retroviral vectors with improved safety, gene expression, and versatility. J. Virol. 72: 994-1004.
36. Hung, G. L., et al. (1994). Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium. Gene Ther. 1: 64-69.
37. Henderson, B., and Pettipher, E. R. (1989). Arthritogenic actions of recombinant IL-1 and tumour necrosis factor-α in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin. Exp. Immunol. 75: 306-310.
38. van de Loo, A. A., et al. (1995). Role of interleukin-1 antigen-induced exacerbations of murine arthritis. Am. J. Pathol. 146: 239-249.
39. Mapp, P. I., et al. (1990). Substance P-, calcitonin gene-related peptide- and C-flanking peptide of neuropeptide Y-immunoreactive fibres are present in normal synovium but depleted in patients with rheumatoid arthritis. neuroscience 37: 143-153.
40. Kidd, B. L., et al. (1995). Neurogenic influences on contralateral responses during experimental rat monoarthritis. Brain Res. 688: 72-76.
41. Decaris, E., et al. (1999). Evidence for neurogenic transmission inducing degenerative cartilage damage distant from local inflammation. Arthritis Rheum. 42: 1951-1960.